What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.
Enovis Corporation: Arvis Is Disrupting The Health Care Industry
Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.
Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land
Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Q2 results beat expectations, with 4% organic revenue growth and improved margins, but guidance now anticipates a more Q4-weighted second half. ENOV is making progress on cash flow conversion and deleveraging, and should reach sub-2.0x net debt/EBITDA within three years.
Enovis Q2 Earnings Call Highlights
Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.
Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript
Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) came out with quarterly earnings of $0.9 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago.
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis Q1 Earnings Call Highlights
Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.
